BIOMAT Database Logo BIOMAT Database Logo

Pharmacogenetic aspects in the metabolism of psychotropic drugs: pharmacokinetic and clinical implications. 1994

E Spina, and A P Caputi
Institute of Pharmacology, University of Messina, Italy.

UI MeSH Term Description Entries
D010597 Pharmacogenetics A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION). Pharmacogenomics
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011619 Psychotropic Drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

E Spina, and A P Caputi
Pharmacokinetic aspects of some behavioral effects of psychotropic drugs.
January 1984, Polish journal of pharmacology and pharmacy,
E Spina, and A P Caputi
Pharmacogenetic Guidelines for Psychotropic Drugs: Optimizing Prescriptions in Clinical Practice.
October 2023, Pharmaceutics,
E Spina, and A P Caputi
Psychotropic drugs and the heart: clinical implications.
January 1980, Progress in neuro-psychopharmacology,
E Spina, and A P Caputi
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
April 2013, Clinical pharmacokinetics,
E Spina, and A P Caputi
[Pharmacokinetic aspects of the effects and interactions of various neuro- and psychotropic drugs].
January 1985, Postepy higieny i medycyny doswiadczalnej,
E Spina, and A P Caputi
Antiepileptic drugs: pharmacokinetic and clinical aspects.
January 1981, Therapeutic drug monitoring,
E Spina, and A P Caputi
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.
January 2002, Epilepsia,
E Spina, and A P Caputi
Metabolism of psychotropic drugs: pharmacological and clinical relevance.
January 1995, Polish journal of pharmacology,
E Spina, and A P Caputi
[Therapeutic monitoring of psychotropic drugs and pharmacogenetic tests in psychiatry].
February 2000, Revue medicale de la Suisse romande,
E Spina, and A P Caputi
Pharmacokinetic and clinical significance of genetic variability in psychotropic drug metabolism.
January 1989, Psychopharmacology series,
Copied contents to your clipboard!